Company research / Focus view

Laurus Labs

LAURUSLABS · Pharma & Healthcare · small cap · Smallcap 50

Revenue · FY26

₹6,721 cr

+22.0% YoY

What the business sold

Net profit · FY26

₹889 cr

+148.0% YoY

What it kept after tax

Operating profit · FY26

₹1,306 cr

+109.0% YoY

Profit from operations

Operating cash flow · FY26

₹1,624 cr

+169.8% YoY

Cash the operations produced

Total debt · FY26

₹2,518 cr

-8.9% YoY

Borrowings against the business

Dividend per share · FY26

—

Paid out per share · not collected yet

Five years in perspective

Price index · Start = 100 · Dividends excluded · ₹1,969 today (+1.23%)

+200.1% · 5Y

2021 · 10020222023202420252026 · 381.7

1M +6.0%6M +89.2%1Y +119.8%3Y +383.3%5Y +200.1%

Market cap

₹1.06 L Cr

As of 13 Sept 2026

Price to earnings

97.1

Price to book 20.1

Dividend yield

12.00%

Trailing twelve months

52-week range

₹823 – ₹1,982

Closing prices

The financial record

₹ crore · Consolidated where reported · Indian fiscal years (April–March)

Reported metric	FY23	FY24	FY25	FY26
Revenue	6,014	5,002	5,508	6,721
Operating profit	1,294	395	625	1,306
Net profit	790	161	358	889
Operating cash flow	994	666	602	1,624
Free cash flow	4	-13	-39	554
Capital expenditure	-990	-678	-641	-1,070
Tax expense	312	68	130	292
Total debt	2,015	2,577	2,764	2,518
Cash and equivalents	46	139	100	113
Shareholders equity	4,038	4,111	4,473	5,300
Earnings per share (₹)	14.64	2.97	6.64	16.45

Not collected yet for this company: Dividend per share. These come from the filings, not the daily price feed.

Recent quarters

₹ crore · Most recent first

Quarter ended	Revenue	Operating profit	Net profit	EPS (₹)
30 Jun 2026	2,026	514	368	6.80
31 Mar 2026	1,812	390	279	5.17
31 Dec 2025	1,778	360	252	4.65
30 Jun 2025	1,570	265	163	3.02
31 Mar 2025	1,720	310	234	4.33

Developments

1 positive · 0 negative

Neutralyesterday

Nifty may rebound to 23,800; Rupak De picks Apollo, Laurus Labs and Eternal for the week

Laurus Labssmall cap Eternal (Zomato)Mentioned

The Economic Times13 Sept 2026, 1:22 pm IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral2 days ago

Laurus Labs Share Price at fresh 52-week high, Rs 1,974

Laurus Labssmall cap

Univest12 Sept 2026, 1:39 pm IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral3 days ago

TORNTPHARM Share Price Today - Torrent Pharmaceuticals on NSE/BSE

Laurus Labssmall cap BSE LtdMentioned Torrent PharmaceuticalsMentioned

scanx.trade11 Sept 2026, 8:25 pm IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral3 days ago

Laurus Labs Share Price

Laurus Labssmall cap

Upstox11 Sept 2026, 7:09 pm IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral3 days ago

Small Cap Stock Laurus Labs Crosses Rs 1 Lakh Crore Market Cap: Are Valuations Justified? Buy, Hold Or Sell?

Laurus Labssmall cap

Dalal Street Investment Journal11 Sept 2026, 5:19 pm IST

Classification & context · Commentary

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Somebody's reading of events rather than an event. Worth the argument; not a filing.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral3 days ago

Paytm, Laurus Labs, Raymond, Chennai Petro hit 52-week high despite weak market sentiment; check full list

Laurus Labssmall cap One 97 Communications (Paytm)Mentioned RaymondMentioned

Upstox11 Sept 2026, 1:32 pm IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral3 days ago

10 smallcap stocks zoom up to 235% in 1 year; 8 turn multibaggers! Own any?

Laurus Labssmall cap

The Economic Times11 Sept 2026, 10:24 am IST

Classification & context · Commentary

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Somebody's reading of events rather than an event. Worth the argument; not a filing.

Classifier confidence: 0.35. This is not the probability that the report is true.

Reads positiveEarnings3 days ago

Laurus Labs profit rises 124% to ₹362 crore in Q1FY27 on CDMO surge

Laurus Labssmall cap

scanx.trade11 Sept 2026, 4:41 am IST

Classification & context · Moves the numbers

The headline states a business fact and a direction that helps it. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.85. This is not the probability that the report is true.

Neutral3 days ago

Multibagger Pharma Stock Up 129% in 1 Year: Why It Rallied

Laurus Labssmall cap

Univest11 Sept 2026, 1:18 am IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

NeutralCash flow5 days ago

5 Pharma CDMO Stocks with Strong Capex Plans

Laurus Labssmall cap

Equitymaster9 Sept 2026, 8:00 am IST

Classification & context · Moves the numbers

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral5 days ago

Trade Spotlight: How should you trade Marico, Narayana Hrudayalaya, Granules, Laurus Labs, Caplin Point,...

Maricomid cap Granules IndiaMentioned Laurus LabsMentioned

Moneycontrol.com9 Sept 2026, 7:45 am IST

Classification & context · Commentary

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Somebody's reading of events rather than an event. Worth the argument; not a filing.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral5 days ago

Trade Spotlight: How should you trade Marico, Narayana Hrudayalaya, Granules, Laurus Labs, Caplin Point, Tata Technologies, and others on September 9?

Laurus Labssmall cap Granules IndiaMentioned MaricoMentioned

TradingView9 Sept 2026, 7:45 am IST

Classification & context · Commentary

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Somebody's reading of events rather than an event. Worth the argument; not a filing.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral6 days ago

Laurus Labs Share Price Today: 3.09% rise and key metrics

Laurus Labssmall cap

Univest8 Sept 2026, 11:34 am IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

About the business

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug product development, and biologics development. In addition, the company offers non-human ingredients; rare disease therapeutics; and finished dosages. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Industry: Drug Manufacturers - Specialty & Generic

www.lauruslabs.com

Data confidence

Prices, fundamentals and developments last verified 13 Sept 2026. Fundamentals are sourced from public filings feeds; interpretation is shown separately from figures.

See the Pharma & Healthcare sector →

Sign in to see the full financial record and classified developments

Guests see a sample. Members get every company, five-year fundamentals, classified developments, a watchlist and the decision journal.